Posts by Ryan J. Sullivan, MD
-
Case Series: Tofacitinib Is Effective in Treating Refractory Immune Checkpoint Inhibitor Hepatitis
Ryan J. Sullivan, MD, Michael L. Dougan, MD, PhD, and colleagues have reported the first three cases of using a Janus kinase (JAK) inhibitor to treat hepatitis associated with immune checkpoint inhibitor therapy. All patients showed excellent response to tofacitinib, although their oncologic outcomes varied.
-
Palbociclib Demonstrates Activity Against Progressive Brain Metastases Harboring CDK Pathway Alterations
A proof-of-concept study at the Massachusetts General Hospital Cancer Center showed genetic testing can guide treatment for patients with brain metastases from solid tumors, as 53% of patients with progressive brain metastases and CDK alterations showed benefit from palbociclib, a CDK inhibitor.
-
Combination Checkpoint Inhibitor Therapy Safe, Extends Survival for Leptomeningeal Disease
In a phase 2 trial, researchers at the Massachusetts General Hospital Cancer Center observed that the combination of two immune checkpoint inhibitors, ipilimumab and nivolumab, was safe and associated with three-month overall survival of 44% in a heavily pretreated population of patients with leptomeningeal disease.
-
Pembrolizumab Promising for Patients with Leptomeningeal Carcinomatosis
Investigators at Massachusetts General Hospital are encouraged by the results of the first prospective clinical trial of an immune checkpoint inhibitor specifically for patients with leptomeningeal dissemination of solid tumors.
Biography
Ryan J. Sullivan, MD, is an Oncologist at Massachusetts General Hospital and associate professor at Harvard Medical School.
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
